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Abstract
Background: Numerous interactions between the coagulation and complement systems have been shown. Recently, links
between coagulation and mannan-binding lectin-associated serine protease-1 (MASP-1) of the complement lectin pathway
have been proposed. Our aim was to investigate MASP-1 activation of factor XIII (FXIII), fibrinogen, prothrombin, and
thrombin-activatable fibrinolysis inhibitor (TAFI) in plasma-based systems, and to analyse effects of MASP-1 on plasma clot
formation, structure and lysis.
Methodology/Principal Findings: We used a FXIII incorporation assay and specific assays to measure the activation
products prothrombin fragment F1+2, fibrinopeptide A (FPA), and activated TAFI (TAFIa). Clot formation and lysis were
assessed by turbidimetric assay. Clot structure was studied by scanning electron microscopy. MASP-1 activated FXIII and,
contrary to thrombin, induced FXIII activity faster in the Val34 than the Leu34 variant. MASP-1-dependent generation of
F1+2, FPA and TAFIa showed a dose-dependent response in normal citrated plasma (NCP), albeit MASP-1 was much less
efficient than FXa or thrombin. MASP-1 activation of prothrombin and TAFI cleavage were confirmed in purified systems. No
FPA generation was observed in prothrombin-depleted plasma. MASP-1 induced clot formation in NCP, affected clot
structure, and prolonged clot lysis.
Conclusions/Significance: We show that MASP-1 interacts with plasma clot formation on different levels and influences
fibrin structure. Although MASP-1-induced fibrin formation is thrombin-dependent, MASP-1 directly activates prothrombin,
FXIII and TAFI. We suggest that MASP-1, in concerted action with other complement and coagulation proteins, may play a
role in fibrin clot formation.
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Introduction
The coagulation and complement systems are activated
following external injury to protect the host from blood loss and
infections. The simultaneous activation of coagulation and
inflammatory processes after injury is a phylogenetically ancient
adaptive response that can be traced back to early eukaryotic
evolution [1]. A number of recent studies show direct interactions
between the two systems [2,3], among them are links between
coagulation factors and mannan (or mannose) -binding lectin
(MBL) associated serine proteases (MASPs) of the complement
lectin pathway.
The lectin pathway of the complement system is activated by
binding of the target recognition molecules MBL or ficolins to
carbohydrates or N-acetylated groups, respectively, on the surface
of cells or microorganisms. MBL and ficolins circulate in
complexes with MASPs which autoactivate upon binding of
MBL/ficolins to their target structures. Three MASPs and two
related proteins are present in human plasma, arising from two
genes by alternative splicing: Mannose-binding lectin-associated
serine protease-1 (MASP-1) and its alternatively-spliced variants
MASP-3 and MAp44, and MASP-2 and its alternatively-spliced
variant MAp19. MAp44 and MAp19 contain no serine protease
domain and hence lack enzymatic activity [4,5]. Average plasma
concentrations of MASP-1 have been estimated at 6 mg/ml (range
1–12 mg/ml) [6] and 11 mg/ml [7].
Upon activation, MASP-2 cleaves both C4 and C2 and thus
induces further complement activation by generating the lectin/
classical pathway C3 convertase C4b2b. Furthermore, MASP-2
cleaves prothrombin to generate active thrombin [8]. In contrast,
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the physiological roles of MASP-1 and MASP-3 remain subject of
research although potential substrates have been identified.
MASP-3 does not activate either C4 or C2. MASP-1 cleaves C2
but not C4 and therefore is not capable of generating C3
convertase alone [9], as confirmed by a study in MASP-2 knockout
mice [10]. Direct activation of C3 by MASP-1 occurs with very
low catalytic efficiency and is not of physiological relevance [4,5].
However, MASP-1 has been suggested to act synergistically with
MASP-2 to produce C3 convertase via C2 cleavage [11], and
MASP-1 may even activate MASP-2 [12,13]. A new role for
MASP-1 in the alternative complement pathway has been
proposed, by directly activating complement factor D [14,15].
MASP-1 may also exert proinflammatory effects through releasing
bradykinin from high-molecular weight kininogen [16].
Experiments with synthetic peptides and structure-function
analyses based on its crystal structure have revealed that MASP-1
has a much broader substrate specificity than MASP-2 and a
thrombin-like activity with similar substrate specificity [9,17,18].
Indeed, MASP-1 is able to cleave the main substrates for
thrombin, fibrinogen and factor XIII (FXIII), and activate
endothelial protease-activated receptor 4, albeit with a lower
catalytic efficiency compared with thrombin [4,19,20]. Cleavage
of the FXIII A-subunit and the fibrinogen b-chain by MASP-1
occur at the same site as proteolysis by thrombin, whereas the
cleavage site in the fibrinogen a-chain is different [19], indicating
potential differences in the mechanisms of fibrin formation by
thrombin and MASP-1. Activation of MASP-1 in complex with L-
ficolin or MBL was also associated with generation of a fibrin clot
[21]. First evidence for an in vivo role of MASP-1 in coagulation
has been recently documented in a study demonstrating that mice
lacking MBL or MASP-1 have a prolonged bleeding time
following tail tip excision [22]. Furthermore, it has been recently
demonstrated in a mouse model of FeCl3-induced intra-arterial
thrombogenesis, that MASP-1 plays a key role in thrombus
formation in vivo [23].
So far, studies on MASP-1 interactions with clotting factors
mainly employed purified systems and cleavage/activation
products of fibrinogen and FXIII were observed by Western
Blotting and HPLC, but the effects of MASP-1 on clot formation
and fibrinolysis in plasma or the characteristics of the clot were not
directly assessed. Fibrin clot structure can determine predisposition
to thrombotic events [24,25], which is related, at least in part, to
fibrinolysis efficiency as clots with denser structure and thinner
fibers are generally more difficult to lyse [26]. The relationship
between clot structure and lysis is in turn related to incorporation
of different plasma proteins into the fibrin network [27]. A
common genetic variant of FXIII, Val34Leu, influences FXIII
activation and cross-linking efficiency leading to altered fibrin
structure [28,29]. Because of its high allele frequency and impact
on thrombotic risk, the FXIII Val34Leu polymorphism is of major
interest when studying fibrin formation and structure in the
context of vascular diseases, but it has so far not been taken into
account in studies investigating MASP-1-induced FXIII activa-
tion. Finally, given the thrombin-like activity of MASP-1, it is
possible that MASP-1 also interacts with another thrombin
substrate, thrombin-activatable fibrinolysis inhibitor (TAFI), which
has not been studied before.
Therefore, the objective of this work was to investigate the effect
of MASP-1 on activation of thrombin-dependent coagulation
factors and fibrin clot formation in plasma environment. The
specific aims were to 1) investigate MASP-1-induced plasma FXIII
activation and analyse the effect of FXIII Val34Leu polymor-
phism, 2) investigate fibrinogen cleavage and activation of
prothrombin and TAFI by MASP-1, and 3) analyse MASP-1-
induced plasma fibrin clot formation, structure and lysis by
turbidimetric assays and scanning electron microscopy.
Methods
Recombinant MASP-1
A recombinant mutant R504Q MASP-1 catalytic fragment,
prepared as described earlier [9,18], was used in this study. It has a
molecular weight of 45.5 kDa and consists of the three C-terminal
domains complement control protein 1 and 2 followed by the
serine protease domain (CCP1-CCP2-SP). The mutant is resistant
to autolysis and preserves its enzymatic activity during prolonged
incubation (estimated half-life of several hours in plasma at 37uC),
otherwise it has the same enzymatic properties as the wild-type
enzyme. To simplify we use the term MASP-1 for the R504Q
rMASP-1 catalytic fragment.
FXIII activation
FXIII activation was assessed using an incorporation assay [28].
Briefly, a microtiter plate was coated with 100 ml/well of
fibrinogen (Sigma-Aldrich, Switzerland) at 40 mg/ml (0.1 mM) in
tris-buffered saline (TBS; 40 mM Tris, 140 mM NaCl, pH 7.4).
After blocking with 200 ml of 1% bovine serum albumin (BSA),
plasma diluted 1/10 as FXIII source or purified FXIII was added
followed by the activation mix to a final reaction volume of 100 ml.
The activation mix contained 5-biotinamidopentylamine (EZ-
LinkH Pentylamine-Biotin, Thermo Scientific, USA), dithiothreitol
(Sigma-Aldrich), and CaCl2, at final concentrations of 0.3 mM,
5 mM, 10 mM, respectively, and human thrombin (Calbiochem,
Merck Biosciences, Switzerland) or MASP-1 at various concen-
trations (as indicated in the results section). The reaction was
incubated at 37uC and stopped at different time points by addition
of 200 mM EDTA. The biotinpentylamine incorporated into
fibrin by FXIIIa was detected by streptavidine-alkaline phospha-
tase (final concentration 1 mg/ml; Sigma-Aldrich), developed with
p-nitrophenylphosphate as substrate, and read at 405 nm, with
620 nm as reference wavelength, on a microplate reader.
Besides normal citrated plasma (NCP; local plasma pool), we
used FXIII-depleted plasma (FXIII-DP; Kordia, The Nether-
lands), and prothrombin-depleted plasma (PT-DP; American
Diagnostica, USA) to show effects independent from thrombin
generation. In some experiments, 1 mM C1 esterase inhibitor from
human plasma (C1-Inh; Sigma-Aldrich) was used. Recombinant
FXIII-A Val34 and FXIII-A Leu34 variants were obtained from
Zedira (Germany).
Fibrin cross-linking by FXIIIa
Fibrin cross-linking analysis by SDS-PAGE was performed to
confirm that fibrin cross-linking occurs in presence of MASP-1.
We incubated 100 ml citrated plasma (normal citrated plasma
NCP or FXIII-depleted plasma FXIII-DP) with 50 ml CaCl2 (final
concentration 5 mM) and 50 ml thrombin (final concentration
0.075 U/ml) or MASP-1 (final concentration 5 mg/ml) at 37uC for
45 min. To two FXIII-DP samples purified FXIII (final
concentration 10 mg/ml) was added. After incubation, samples
were spun down at 10’000 g for 10 min, the supernatants were
removed and the clots washed twice in 1 ml TBS. After the last
wash, 800 ml Laemmli sample buffer (Bio-Rad Laboratories,
Hercules, USA) with b-mercaptoethanol was added and the
samples were boiled at 95uC for 15 min to solubilize the clots.
Purified fibrinogen (Calbiochem; final concentration 0.2 mg/ml)
was used as control. Twenty microliters were loaded onto a 7.5%
Tris-Glycine Mini-ProteanH TGXTM gel (Bio-Rad). The gel was
stained with Bio-SafeTM Coomassie (Bio-Rad).
MASP-1 and Plasma Clot Formation
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Fibrinogen cleavage and activation of prothrombin and
TAFI
Cleavage of fibrinogen and activation of prothrombin were
studied in NCP and PT-DP. Plasma samples (400 ml) were
incubated at 37uC for 30 min with 100 ml of either TBS buffer
only (non-activated, negative control), human thrombin (Calbio-
chem) at a final concentration of 0.1 U/ml (2.8 nM), human FXa
(Hyphen BioMed, Neuville-sur-Oise, France) at a final concen-
tration of 0.1 mg/ml (2.2 nM) with 6 mM CaCl2, or MASP-1 at
final concentrations of 20 mg/ml (440 nM), 10 mg/ml (220 nM),
5 mg/ml (110 nM), 2.5 mg/ml (55 nM). Samples were then spun
down at 10’000 g for 10 min, and the supernatant was snap-frozen
in aliquots. For confirmation of prothrombin cleavage in a purified
system, 100 ml of human prothrombin (Hyphen BioMed) at
100 mg/ml (1.4 mM) were incubated at 37uC with FXa at a final
concentration of 0.1 mg/ml (2.2 nM)62.5 mM CaCl2 or MASP-1
at final concentrations of 20 mg/ml (440 nM), 10 mg/ml (220 nM),
5 mg/ml (110 nM), 2.5 mg/ml (55 nM). At 5, 10, 15, and 30 min
samples were snap-frozen. F1+2 was measured using the
EnzygnostH F1+2 ELISA kit (Siemens Healthcare, Marburg,
Germany). FPA was determined with the Zymutest FPA ELISA kit
(Hyphen BioMed).
TAFI activation in plasma was analysed with the ActichromeH
TAFI activity kit (American Diagnostica Inc, Stamford CT, USA).
NCP and PT-DP, diluted 1/25, were incubated for 20 min with
an activation mix containing either thrombin-thrombomodulin
complex (final thrombin concentration 80–100 nM) or MASP-1 at
final concentrations of 50 mg/ml (1100 nM), 10 mg/ml (220 nM),
or 2 mg/ml (44 nM). Non-activated plasma was assayed in
parallel. After stopping the activation reaction, activated TAFIa
was detected with a highly specific TAFIa substrate. The
concentration of TAFIa was calculated as the difference between
activated and non-activated plasma samples.
TAFI cleavage by MASP-1 was verified using SDS-PAGE. To
investigate the dose-dependent effect of MASP-1 on TAFI,
200 mg/ml (3.45 mM) of purified TAFI (Enzyme Research
Laboratories, South Bend, USA) were incubated for 30 min at
37uC with MASP-1 at final concentrations of 100 mg/ml (2.2 mM),
200 mg/ml (4.4 mM), 400 mg/ml (8.8 mM), or 800 mg/ml
(17.6 mM), diluted in TBS (40 mM Tris, 140 mM NaCl,
pH 7.4). To investigate the time-dependent effect of MASP-1 on
TAFI, 200 mg/ml (3.45 mM) of purified TAFI were incubated for
30 min, 60 min, and 120 min at 37uC without and with 400 mg/
ml (8.8 mM) MASP-1. To confirm MASP-1-induced TAFI
cleavage at physiological concentrations and compare it to
thrombin/thrombomodulin-induced TAFI cleavage, the following
experiment was performed: In a reaction volume of 50 ml, we
incubated 15 mg/ml TAFI with either 15 mg/ml rMASP-1 or
1.7 U/ml (50 nM) thrombin and 3 mg/ml (58 nM) thrombomo-
dulin (Abcam, Cambridge, UK) at 37uC for 1 h. This was similar
to a protocol by Bajzar et al. [30]. After the incubation steps,
reactions were stopped by adding Laemmli sample buffer (Bio-
Rad Laboratories, Hercules, USA) containing b-mercaptoethanol,
followed by boiling at 95uC for 10 min. Samples were run on Any
kDTM Mini-ProteanH TGXTM gels (Bio-Rad) and gels were
stained with Bio-SafeTM Coomassie.
Turbidimetric clot formation and lysis assay
Plasma clot formation and lysis was measured using a method
adapted from Carter et al. [31]. Briefly, 25 ml of citrated plasma
Figure 1. MASP-1-induced FXIII activation. Activation of FXIII was
determined in a FXIII incorporation assay. (A) In a purified system,
increasing MASP-1 concentrations were associated with increased FXIII
activity, while C1-Inhibitor abolished MASP-1-induced FXIII activity. (B)
In normal plasma, FXIII activation by MASP-1 occurred in a time-
dependent (B) and dose-dependent (C) manner. (D) MASP-1 also
activated FXIII in prothrombin-depleted plasma. Data points represent
mean values from two (panels B and D) or three (panels A and C)
experiments with error bars representing standard deviation.
doi:10.1371/journal.pone.0035690.g001
MASP-1 and Plasma Clot Formation
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and 75 ml of TBS (50 mM Tris, 100 mM NaCl, pH 7.4) per well
were added to a 96-well microtiter plate (Greiner bio-one,
Germany). In the lysis assay, the 75 ml of TBS contained tPA
(final concentration 83 ng/ml (1.2 nM)) (Technoclone, Austria).
Upon addition of 50 ml of activation mix containing MASP-1 at
various concentrations (see results section) or 0.03 U/ml (0.8 nM)
(final concentration) human thrombin (Calbiochem) and 2.5 mM
(final concentration) CaCl2 in TBS, the plate was placed into a
microplate reader and optical density at 340 nm was recorded at
37uC every 30 sec for up to 2.5 hours. We analyzed the
parameters lag time (time between addition of activation mix
and exponential increase in absorbance), maximum absorbance
(corrected for baseline absorbance), and lysis time (time between
maximum absorbance and return to baseline absorbance). The
turbidimetric assays were performed in NCP and PT-DP (to
exclude thrombin action).
Scanning electron microscopy of plasma clots
Forty-five microliters of normal citrated plasma diluted 1/2 with
TBS were clotted upon the addition of 5 ul activation mix
containing CaCl2 (final concentration 5 mM) and either thrombin
(final concentration 0.88 U/ml (24 nM)) or different concentra-
tions of MASP-1 (final concentrations 1 mg/ml (22 nM), 5 mg/ml
(110 nM) or 10 mg/ml (220 nM)). As described earlier [27], clots
were made in specially devised small perforated plastic vessels,
incubated in a moist chamber for 2 hours followed by washing
with sodium cacodylate buffer and subsequently fixed for 30 mins
in 2% glutaraldehyde. Clots were recovered and further processed
Figure 2. Activation of recombinant FXIII Val34 and Leu34 variants by MASP-1. (A) In a purified system, thrombin activated the Leu34
variant faster than the Val34 variant, whereas MASP-1 activated the Val34 variant faster than the Leu34 variant. (B) When added to FXIII-depleted
plasma the same results in regard to Val34Leu variants were observed, but MASP-1-induced FXIII activation was less efficient compared to thrombin.
Data points represent mean values from two experiments with error bars representing standard deviation.
doi:10.1371/journal.pone.0035690.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35690
by a stepwise dehydration with acetone gradient and sputter
coated with platinum palladium. Samples were viewed and
photographed using a field emission gun, environmental scanning
electron microscope (FEI, Quanta 200F, Hillsboro, USA). Ten
images from different areas at three different magnifications
(50006, 100006, 300006) were taken per clot and visually
examined by several investigators blinded to the clotting agent.
Fiber diameters were measured with image analysis software
package ImageJ 1.44p (Wayne Rasband, National Institutes of
Health, USA, http//:imagej.nih.gov/ij). Ten fibers per image,
corresponding to 100 fibers per clot, were measured. Fiber
diameter data were normally distributed and compared between
the four groups of clots (thrombin, MASP-1 10 mg/ml, MASP-1
5 mg/ml, MASP-1 1 mg/ml) by Oneway ANOVA with post-hoc
Bonferroni analysis (SPSS Statistics software, version 17.0.0).
Summary of statistical methods
Experiments were performed several times, as described for the
individual experiments, and results are shown as mean and
standard deviation (SD) unless stated otherwise. In figures, data
points represent mean values with error bars representing SD.
SPSS Statistics software, version 17.0.0 (SPSS Inc.) was used for
statistical analyses. Associations between MASP-1 concentration
and parameters of the turbidimetric clot formation and lysis assay,
i.e. lag time, maximum absorbance, and lysis time, were assessed
using bivariate correlation analysis and expressed as Pearson
correlation coefficient. Data on fibrin fiber diameters obtained
from SEM of thrombin and MASP-1 clots were tested for normal
distribution using the Kolmogorov-Smirnov test. Fiber diameters
were compared between the four groups using the Oneway
ANOVA and pairwise comparisons were analyzed using the post-
hoc Bonferroni method.
Results
FXIII activation
In a purified system with 20 mg/ml (62 nM) of FXIII, MASP-1
induced FXIII-dependent biotin incorporation in a dose-depen-
dent manner, whereas no incorporation was observed without
FXIII or in the presence of 100 mg/ml (1 mM) of C1 inhibitor
(Fig. 1a). In normal plasma (final dilution 1/25), MASP-1 induced
FXIII-dependent biotin incorporation in a time- and dose-
dependent manner (Fig. 1b, 1c). In the purified system, MASP-
1-induced FXIII activation was evident at 5 min, whereas in
plasma environment no effect was observed until 40 min, in
contrast to thrombin which showed an early effect. No
incorporation was observed in FXIII-depleted plasma (data not
shown), whereas MASP-1 also induced FXIII-dependent biotin
incorporation in prothrombin-depleted plasma (Fig. 1d), albeit less
efficiently compared with normal plasma (Fig. 1b).
When recombinant FXIII A-subunit Val34 and Leu34 variants
were tested in TBS containing 1% BSA or in FXIII-depleted
plasma, thrombin induced FXIII activity faster in the Leu34
variant compared to the Val34 variant, whereas the results were
the opposite with MASP-1 which induced FXIII activity faster in
the Val34 variant than the Leu34 variant (Fig. 2a, 2b). In the
purified system, activation of FXIII Leu34 by thrombin or MASP-
1 was similar, whereas FXIII Val34 activation showed large
differences, with far superior activation achieved with MASP-1. In
FXIII-DP, MASP-1 was again less efficient at activating FXIII,
with both Val34 and Leu34 variant demonstrating higher
activation by thrombin, in contrast to purified data. However,
Val34 variant was still more efficiently activated by MASP-1
compared with Leu, in contrast to thrombin.
Fibrin cross-linking by FXIIIa
Fig. 3 shows fibrin cross-linking by FXIIIa. Upon activation
with thrombin and Ca2+ (lane 3), the fibrinogen Aa-chain (labelled
a) was cleaved and partly formed high-molecular-weight an
polymers, the fibrinogen Bb-chain (labelled b) was cleaved, and
the fibrinogen c-chain (labelled c) completely disappeared to form
c-c dimers. When NCP was incubated with MASP-1 (lane 4), the
same cross-linking pattern appeared. No cross-linking was seen in
FXIII-DP (lanes 5 and 6), but could be restored by addition of
FXIII (lanes 7 and 8) confirming that this process was depending
on FXIII.
MASP-1 and activation/cleavage of prothrombin,
fibrinogen, and TAFI
When MASP-1 was added to NCP, a dose-dependent
generation of the prothrombin activation product, prothrombin
fragment F1+2, was observed, although it was far less efficient than
FXa (Table 1, Fig. 4a). We confirmed prothrombin cleavage by
MASP-1 in a purified system which showed a dose- and time-
response (Fig. 4b). In NCP, MASP-1 concentration correlated with
generation of the fibrinogen cleavage product FPA, although it
was again far less efficient than thrombin (Table 1, Fig. 4c). Using
PT-DP, thrombin had similar effects on FPA generation compared
with NCP, whereas MASP-1 showed only negligible FPA
generation and failed to demonstrate a dose-response effect
(Table 1, Fig. 4c). This suggests that in a plasma system, MASP-
1-induced FPA cleavage is largely thrombin-dependent and
secondary to prothrombin activation by MASP-1.
In addition to prothrombotic factors, MASP-1 is capable of
activating the antifibrinolytic protein TAFI. Using NCP, MASP-1
activated TAFI in a dose-dependent manner, although high
concentrations were needed to show an effect and this was still
Figure 3. Fibrin crosslinking by FXIIIa. When thrombin or MASP-1
were incubated with NCP or FXIII-DP with added FXIII, c-c dimers and
an polymers were formed. No crosslinks were formed in FXIII-DP. Lane
1: Molecular weight marker. Lane 2: Purified fibrinogen. Lane 3:
NCP+Ca2++thrombin. Lane 4: NCP+Ca2++MASP-1. Lane 5: FXIII-
DP+Ca2++thrombin. Lane 6: FXIII-DP+Ca2++MASP-1. Lane 7: FXIII-
DP+FXIII+Ca2++thrombin. Lane 8: FXIII-DP+FXIII+Ca2++MASP-1. Lane 9:
Purified fibrinogen. Lane 10: Molecular weight marker.
doi:10.1371/journal.pone.0035690.g003
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around 10-fold lower than the activation achieved by the
physiological TAFI activator thrombin-thrombomodulin complex
(Table 1). MASP-1 also activated TAFI in PT-DP indicating that
this process is not thrombin-dependent. Cleavage of TAFI by
MASP-1 in a dose- (Fig. 5a) and time-dependent (Fig. 5b) manner
was confirmed by SDS-PAGE. Again, MASP-1 was less efficient at
cleaving TAFI than thrombin/thrombomodulin (Fig. 5c).
Clot formation, structure and lysis using turbidimetric
assays
MASP-1 induced clot formation in NCP, but not in PT-DP (not
even at MASP-1 concentrations up to 100 mg/ml (2.2 mM)). This
is in agreement with our FPA data above and suggests that in
plasma environment fibrin formation is not directly induced by
MASP-1 in the absence of prothrombin.
MASP-1 had no clear influence on the initiation of clot
formation in NCP assessed as lag time. However, addition of
MASP-1 resulted in prolongation of lysis time, with maximum
prolongation at 1 mg/ml (22 nM) but no additional effect at higher
MASP-1 concentrations (Fig. 6a). Furthermore, MASP-1 had a
dose-dependent effect on plasma clot maximum absorbance
(Fig. 6b). MASP-1 concentrations between 0 and 8 mg/ml
(176 nM) showed significant inverse correlation with maximum
absorbance (Pearson correlation coefficient 20.964, p,0.001).
These results suggested that higher MASP-1 concentrations were
associated with either thinner fibers or reduction in clot density.
Fibrin structure by SEM
Clots prepared with thrombin (Fig. 7d) were characterized by a
dense fibrin network with thin fibers with a mean (SD) diameter of
102 (18) nm and small pores. In contrast, clots prepared in
presence of MASP-1 (Fig. 7a–c) showed a less dense network with
coarser fibers and larger pores. The mean (SD) fiber diameters of
clots made with 1 mg/ml (22 nM), 5 mg/ml (110 nM) or 10 mg/ml
(220 nM) of MASP-1 were 108 (17) nm, 120 (17) nm, and 134 (22)
nm, respectively. Fiber diameters of MASP-1 clots were
significantly higher than thrombin clots (p,.001), except for clots
prepared with 1 mg/ml MASP-1 (p = .097).
Role for MASP-1 in plasma clot formation
Taken together, we propose the following role for MASP-1 in
plasma clot formation, as summarized in Fig. 8. MASP-1 initiates
fibrin clot formation by converting prothrombin to thrombin
which then cleaves fibrinogen. MASP-1 activates FXIII indepen-
dently from thrombin, having a greater effect on Val34 variant
compared with Leu34, which is the opposite to thrombin. MASP-
1 induces changes in fibrin clot structure that may be related to
different plasma protein incorporation into the clot secondary to
altered FXIII activation. This, together with direct TAFI
Figure 4. Activation of prothrombin, fibrinogen, and TAFI. (A) MASP-1 induced generation of the activation marker prothrombin fragment
F1+2 in normal plasma. (B) Dose- and time-dependent prothrombin cleavage by MASP-1 was confirmed using purified proteins. (C) MASP-1 was
associated with generation of the activation marker fibrinopeptide-A (FPA) in normal plasma (NCP) but not in prothrombin-depleted plasma (PT-DP).
Data points represent mean values from two experiments with error bars representing standard deviation.
doi:10.1371/journal.pone.0035690.g004
Table 1. Activation products of prothrombin, fibrinogen, and TAFI.
NCP PT-DP
Activation by F1+2 (pmol/l) F1+2 (pmol/l)
FXa 0.1 mg/ml (2.2 nM) 136417.0 Not applicable
MASP-1 20 mg/ml (440 nM) 689.3 Not applicable
MASP-1 10 mg/ml (220 nM) 461.2 Not applicable
MASP-1 5 mg/ml (110 nM) 299.9 Not applicable
MASP-1 2.5 mg/ml (55 nM) 232.2 Not applicable
No activation 136.0 Not applicable
Activation by FPA (nmol/l) FPA (nmol/l)
Thrombin 0.1 U/ml (2.8 nM) 556.6 516.9
MASP-1 20 mg/ml (440 nM) 18.7 4.2
MASP-1 10 mg/ml (220 nM) 12.3 4.0
MASP-1 5 mg/ml (110 nM) 7.8 4.0
MASP-1 2.5 mg/ml (55 nM) 4.8 4.0
No activation ,0.4 2.4
Activation by TAFIa (nmol/l) TAFIa (nmol/l)
Thrombin-thrombomodulin 360.3 549.1
MASP-1 50 mg/ml (1000 nM) 38.9 44.0
MASP-1 10 mg/ml (220 nM) 7.4 10.9
MASP-1 2 mg/ml (44 nM) 1.4 3.1
Activation products were measured in normal citrated plasma (NCP) and prothrombin-depleted plasma (PT-DP). Data are shown as mean (n = 2). TAFIa results are
corrected for the non-activated samples, therefore no values for the non-activated samples are shown.
doi:10.1371/journal.pone.0035690.t001
MASP-1 and Plasma Clot Formation
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35690
activation by MASP-1, may be responsible for longer lysis time of
clots formed following MASP-1 activation.
Discussion
There is increasing interest in and mounting evidence for a role
of the complement system in atherosclerosis [32]. In addition,
more interactions between complement and coagulation are being
discovered which could provide pathophysiological mechanisms
linking inflammatory and thrombotic processes. The aim of the
present work was to study interactions between MASP-1 and
coagulation factors involved in fibrin formation in plasma and
investigate whether MASP-1 is able to induce plasma clot
formation independently from activation of coagulation pathways.
Completely novel aspects of our work compared with earlier
studies include the following: 1) experiments were performed in
plasma environment, 2) we employed state of the art coagulation
tests including sensitive activation tests and a turbidimetric clot
formation and lysis test, 3) for the first time we studied the
activation of both FXIII Val34 and Leu34 genetic variants by
MASP-1, 4) we investigated for the first time MASP-1 effects on
TAFI, and 5) we studied for the first time the structure of plasma
clots made in presence of MASP-1 using SEM.
We showed that MASP-1 activates FXIII in plasma in a dose-
dependent manner and independently from thrombin activity,
albeit less efficiently compared to thrombin. MASP-1 specificity
was further confirmed by inhibition of FXIII activation in the
presence of C1-inhibitor. MASP-1 was slower at activating FXIII
in plasma environment, with similar results observed in normal
and prothrombin-depleted plasma, than in the purified system.
This suggests that plasma contains factors that inhibit MASP-1-
induced FXIII activation, but it also shows that MASP-1
activation of FXIII can occur directly and is not only thrombin-
dependent. However, in plasma environment most FXIII
activation by MASP-1 is probably mediated by thrombin and
sufficient FXIIIa is generated to support normal fibrin cross-
linking as shown by our cross-linking analysis. On the other hand,
it is known that only traces (,1%) of FXIIIa are sufficient for
fibrin cross-linking [33], so even in the absence of thrombin the
FXIIIa directly generated by MASP-1 would be enough to cross-
link any fibrin or other proteins. One striking observation was the
difference in MASP-1-induced activation of FXIII genetic
variants. The common FXIII Val34Leu polymorphism leads to
altered FXIII activation by thrombin [28,29]. The FXIII A-
subunit residue at position P(4) from the thrombin cleavage site,
corresponding to Val34, is important for recognition and binding
of thrombin and hence FXIII activation [34,35]. Due to its higher
affinity to thrombin, the Leu34 variant is activated at a faster rate
and paradoxically this variant protects from cardiovascular disease
in most clinical studies [36]. Studies have struggled to explain this
paradox and several hypotheses have been put forward including
an interaction with fibrinogen levels and less efficient cross-linking
of various proteins into the clot [29,37,38]. In our work, however,
we have shown that MASP-1 activated the wild-type Val34 variant
faster than the Leu34 variant, both in a purified system and in
plasma environment. This suggests that i) MASP-1 activates FXIII
in a different manner compared with thrombin possibly due to
differences in substrate recognition and ii) interaction between the
complement system and FXIII activation in vivo may contribute, at
least in part, to the higher prevalence of thrombotic events with
FXIII Val34 variant. Further work to elucidate the mechanisms
behind this intriguing novel observation remains an area for future
studies, including experiments at different fibrinogen concentra-
Figure 5. Cleavage of TAFI visualized by SDS-PAGE. (A) Dose-
dependent effect of MASP-1 on cleavage of TAFI. Lane 1: Molecular
weight marker. Lane 2: TAFI 200 mg/ml. Lane 3: TAFI+100 mg/ml MASP-
1. Lane 4: TAFI+200 mg/ml MASP-1. Lane 5: TAFI+400 mg/ml MASP-1.
Lane 6: TAFI+800 mg/ml MASP-1. (B) Time course of MASP-1 cleavage of
TAFI. TAFI (200 mg/ml) was incubated at 37uC without or with MASP-1
(400 mg/ml). When TAFI was incubated without MASP-1, no cleavage
occurred. Lane 1: Molecular weight marker. Lane 2: MASP-1 (fresh
control). Lane 3: TAFI (fresh control). Lane 4: TAFI incubated for 30 min.
Lane 5: TAFI+MASP-1 incubated for 30 min. Lane 6: TAFI incubated for
60 min. Lane 7: TAFI+MASP-1 incubated for 60 min. Lane 8: TAFI
incubated for 120 min. Lane 9: TAFI+MASP-1 incubated for 120 min. (C)
Physiological concentrations of TAFI (15 mg/ml) were incubated with
either physiological concentrations of MASP-1 (15 mg/ml) or 1.7 U/ml
(50 nM) thrombin and 3 mg/ml (58 nM) thrombomodulin. Lane 1:
Molecular weight marker. Lane 2: TAFI. Lane 3: TAFI+MASP-1. Lane 4:
TAFI+thrombin/thrombomodulin. In all three panels, arrows indicate
full-length TAFI (58 kDa) and activated TAFIa (35 kDa).
doi:10.1371/journal.pone.0035690.g005
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tions since the protective effect of the FXIII Leu34 variant is
strongest at high fibrinogen concentrations.
We also tested MASP-1-induced cleavage/activation of two
other major thrombin substrates in plasma, fibrinogen and TAFI.
Cleavage of the fibrinogen a-chain by MASP-1 has been suggested
to occur at different sites compared with thrombin [19]. We have
therefore tested whether MASP-1 induces the generation of FPA
in plasma environment. In NCP, FPA generation correlated with
MASP-1 concentration, but the quantities of FPA generated were
much lower compared with thrombin. In PT-DP, negligible
amounts of FPA were detected which failed to show a MASP-1
dose-response, suggesting that MASP-1-induced release of FPA
relies on presence of prothrombin and possibly on thrombin
generation. These findings support earlier data that fibrinogen
cleavage by MASP-1 does not produce FPA [19] and suggest that
direct cleavage of fibrinogen, and FXIII, by MASP-1 is probably
of minor importance in plasma. The essential role of prothrombin
is supported by our data demonstrating the inability of MASP-1 to
induce fibrin clot formation in PT-DP in the turbidimetric assay,
and the ability of MASP-1 to cleave prothrombin in a dose-
dependent manner. Despite of the apparently better performance
of MASP-1 than FXa in cleaving prothrombin in a purified system
(Fig. 4b), it must be noted that FXa activity is underestimated in
this system due to the lack of its prothrombinase complex cofactor
FVa and phospholipids. In plasma (Table 1), prothrombin
cleavage by MASP-1, similar to prothrombin cleavage by
MASP-2 described by Krarup et al. [8], is much less effective
compared to FXa, and would even be less effective when
compared with the prothrombinase complex. However, thanks
to its efficient amplification system, tiny amounts of generated
Figure 6. Effects of MASP-1 on plasma clot lysis time and maximum absorbance. Clot formation and lysis in normal plasma were
investigated using a turbidimetric assay. Increasing MASP-1 concentrations were associated with longer clot lysis time (A) and lower maximum
absorbance (B). Data points represent mean values from three experiments with error bars representing standard deviation.
doi:10.1371/journal.pone.0035690.g006
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thrombin can trigger significant activation of the coagulation
cascade. We confirmed MASP-1 cleavage of prothrombin in a
purified system, since this reaction had been excluded for MASP-1
earlier [8]. The discrepancy between our results and the study by
Krarup et al. [8] may be explained by i) different experimental
conditions, ii) difference in concentrations of tested proteins, and ii)
different methods to detect prothrombin activation products.
Krarup et al. used prothrombin at a final concentration of
110 mg/ml, MASP-1 at 1 mg/ml. We used a similar prothrombin
concentration but MASP-1 was used at a wider range of
physiological concentrations of 2.5–20 mg/ml. Also, Krarup et
al. detected prothrombin cleavage by SDS-PAGE and Coomassie
staining. Our method of detecting prothrombin fragment F1+2 by
ELISA may be more sensitive.
In contrast to PT-DP, MASP-1 induced clot formation in NCP
and an inverse correlation was detected between clot final
turbidity and MASP-1 concentrations, indicating this protein
modulates the final structure of the clot, which has not been
documented before. It is accepted that lower maximum absor-
bance of clots made using purified systems indicates the formation
of thinner fibers, but in plasma clots this is more complex as
reduced maximum absorbance may be an indicator of thinner
fibrin fibers and/or decreased clot density. MASP-1 has also
affected clot structure as assessed by SEM. Clots made in the
presence of MASP-1 had thicker fibers, were less dense and more
porous compared with clots made after thrombin activation. Thus,
results from the turbidimetric clotting assay and SEM both suggest
that MASP-1 leads to a less dense clot structure with thicker fibrin
Figure 7. Fibrin structure assessed by SEM. Representative images of plasma clots prepared with (A) 1 mg/ml (22 nM) MASP-1, (B) 5 mg/ml
(110 nM) MASP-1, (C) 10 mg/ml (220 nM) MASP-1, or (D) 0.88 U/ml (24 nM) of thrombin (magnification 50006). Clots prepared in presence of MASP-1
showed a less dense structure with larger pores and thicker fibers.
doi:10.1371/journal.pone.0035690.g007
Figure 8. The proposed role of MASP-1 in plasma clot
formation. MASP-1 induces fibrin clot formation by converting
prothrombin to thrombin which then cleaves fibrinogen. MASP-1
activates FXIII and TAFI independently albeit at a lower efficiency than
thrombin. Changes in clot structure and TAFI activation by MASP-1 may
be responsible for prolonged lysis time of clots made in the presence of
MASP-1. The finer arrows for MASP-1-dependent reactions, as
compared with thrombin-dependent reactions, represent the fact that
in plasma MASP-1 is less efficient compared with thrombin. The
mechanisms underlying the impact of MASP-1 on fibrin structure
remain to be elucidated.
doi:10.1371/journal.pone.0035690.g008
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fibers. It is well established that thrombin concentrations have a
major impact on fibrin structure, with increasing thrombin
concentrations resulting in a denser fibrin network with thinner
fibers [39–41]. Intriguingly, MASP-1 seems to have the opposite
effect as increasing MASP-1 concentrations were associated with
less dense fibrin networks and thicker fibers, suggesting that a
mechanism other than increased thrombin generation may be
involved. So far, however, the way MASP-1 alters clot
characteristics remains unclear. Although we show that fibrin
formation in plasma is mainly thrombin-dependent, MASP-1 may
interfere with prothrombin and fibrinogen resulting in slower
production of fibrin monomers. Lower polymerization rates are
known to produce a looser network with thicker fibers [39]. It has
also been suggested that FPB release from the fibrinogen b-chain
promotes lateral aggregation resulting in formation of thick fibers
[42,41]. Thus, additional FPB cleavage by MASP-1, as shown by
Krarup et al. [19], may just have this effect. In addition, the
observed differences in clot structure associated with MASP-1 may
be related to different activation of FXIII and altered cross-linking
of various proteins. These observations may also be in line with
results by Gulla et al. [21] who suggested a similar clot
composition but less cross-linking of clots made with MASP-1.
We show for the first time that MASP-1 is able to activate
TAFI. This reaction is independent of thrombin generation as it
was observed in both NCP and PT-DP and confirmed by SDS-
PAGE. It should be noted, however, that MASP-1 activation of
TAFI occurs at a much lower efficiency compared with thrombin/
thrombomodulin. Nevertheless, additional TAFI activation by
MASP-1 may explain the prolongation of lysis time associated with
MASP-1 in the turbidimetric clotting and lysis assay, since TAFI is
a major inhibitor of fibrinolysis. Another possible explanation for
prolongation of lysis time may be the interaction between MASP-1
and FXIII which may lead to changes in fibrin cross-linking and
cross-linking of antifibrinolytic proteins to fibrin, which in turn
affects efficiency of fibrinolysis.
A less dense clot structure is generally associated with shorter
lysis times, whereas we see longer lysis times of plasma clots made
in the presence of MASP-1. Whether the profibrinolytic effect of a
less dense network or the antifibrinolytic effect observed in the
turbidimetric assay prevails in vivo remains to be investigated. If
MASP-1 indeed led to prolongation of fibrinolysis, this would
represent a further link between the complement system, in
particular MBL pathway components, and changes in fibrin clot
structure and prolongation of fibrinolysis, as our group has
previously shown an independent association between comple-
ment C3 levels and prolongation of fibrinolysis [43–45].
A limitation of our study is the use of a recombinant mutant
catalytic fragment of MASP-1 instead of the full-length molecule.
We used this catalytic fragment for the following reasons: First of
all, at present there is no appropriate method to purify native
MASP-1 from plasma or serum and consequently several attempts
to purify MASP-1 in sufficient amounts and free from contam-
ination with other MASPs have failed. In addition, recombinant
expression of full-length MASP-1 failed in all expression systems.
In eukaryotic cells wild type MASP-1 is toxic. The recombinant
MASP-1 constructs which could be expressed (e.g. in CHO cells)
were mutants in the catalytic domain leading to reduced
proteolytic efficiency. In contrast, the recombinant MASP-1
fragment we used in our study is the only preparation in the
world which represents the wild type active human MASP-1. We
are aware that, unlike the native protein, this catalytic fragment
cannot form dimers or bind to MBL or ficolins and does not
require an activation step and may therefore behave differently.
However, the CUB-EGF-CUB domains, which are deleted in our
fragment but present in the C1r, C1s and MASP proteins, are
engaged in binding to the recognition molecules and consequently
do not take part in substrate binding. The CCP modules, however,
can contain exosites for substrate binding, as demonstrated for
MASP-2 and C1s. Accordingly, our catalytic MASP-1 fragment
contains both CCP modules. In addition, recombinant catalytic
fragments of C1r, a MASP homolog, have been shown to retain
the catalytic efficiency and substrate specificity of the entire
molecule [9]. Endogenous MASP-1 circulates in plasma as a
zymogen. The active recombinant fragment, rMASP-1 CCP1-
CCP2-SP, we used in our study might activate the endogenous
zymogen. In addition, it might also activate MASP-2 as recently
shown [13]. However, in both cases the measured effects would
still be due to MASP-1. Taken together, we do believe that the
catalytic MASP-1 fragment we have used in our study represents
the best model protein currently available to achieve our main
goal which was to investigate MASP-1 catalytic properties towards
coagulation proteins in plasma.
In summary, we used an array of coagulation factor activation
and plasma clotting assays as well as SEM of plasma clots to show
that MASP-1, albeit not able to induce fibrin clot formation
completely independently of coagulation activation, interacts with
plasma clot formation on different levels and influences the
resulting fibrin structure. MASP-1 activates FXIII independently
from thrombin and has a differential effect on FXIII Val34 and
Leu34 variants. On the other hand, fibrinogen-to-fibrin conver-
sion by MASP-1 is related to thrombin generation through
prothrombin activation. Fibrin clot formation can be initiated by
MASP-1 in plasma and this has an effect on lysis time, which may
be related to changes in clot structure, activation of FXIII and
TAFI, or other unknown factors. Our results support the first in
vivo findings for a role of MASP-1 in coagulation and thrombus
formation [22,23], but further investigations to elucidate the
precise mechanisms and physiological relevance in humans are
needed. Nevertheless, our results are consistent with a possible role
for MASP-1 in plasma fibrin clot formation and fibrinolysis, which
may have future clinical implications.
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